Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...

Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...

HOUSTON, TX — Nearly one in five patients treated with prasugrel (Effient, Lilly/Daiichi Sankyo) in the PINNACLE registry is receiving the drug inappropriately or for a nonrecommended indication, ...

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and multivessel coronary artery disease who had PCI, ticagrelor was not noninferior to ...

In order to better prevent blood clots, the drugs clopidogrel or prasugrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

heart ecg A systematic review and meta-analysis published in the American Journal of Cardiovascular Drugs compared the safety and efficacy of prasugrel and ticagrelor in patients with acute coronary ...

Pretreatment with clopidogrel should not prohibit reloading with prasugrel in patients presenting with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention (PCI), according ...

Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. To ...

UPDATE: Dr. Sanjay Kaul was bounced from the FDA's prasugrel panel after Eli Lilly called the FDA to question his inclusion on the panel, according to HeartWire. The FDA has admitted it made a ...

TOKYO and INDIANAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee voted 9 to 0 that ...

Although P2Y 12 antagonists are effective in patients with non–ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration — before or after coronary angiography — ...

In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...